--- title: Nanotalks, Curapath blog description: Explore Curapath's blog dive into PNP and LNP formulations, GMP manufacturing, and solutions for non-viral gene therapy, all this in Nanotalks by Curapath image: https://blog.curapath.com/hubfs/Captura%20de%20pantalla%202025-03-10%20102446.png --- [Skip to content](https://blog.curapath.com#main-content) [![White](https://blog.curapath.com/hs-fs/hubfs/White.png?width=553&height=208&name=White.png "White")](https://curapath.com/) - [Resources](https://resources.curapath.com/en/curapath-resource-library) - [End to end services](https://curapath.com/end-to-end-services/) - [Expertise](https://curapath.com/expertise/) - [Products](https://curapath.com/products) - [Blog](https://blog.curapath.com) - [Contact Us](https://curapath.com/contact-us/)  ![](https://blog.curapath.com/hs-fs/hubfs/logo%20Nanotalks%20blog%20Curapath%20banco-png.png?width=6000&height=3375&name=logo%20Nanotalks%20blog%20Curapath%20banco-png.png) NanoTalks by Curapath is your gateway to the future of healthcare nanotechnology. In each episode, we explore the latest trends in lipid and polymer nanoparticles a groundbreaking field transforming how next-generation therapies and vaccines are developed. Discover how these tiny, multifunctional structures can enhance treatment effectiveness, minimize side effects, and open the door to innovations that once seemed out of reach. Join us as we delve into cutting-edge research, clinical insights, and the major advances shaping modern medicine Hot topics # NanoTalks - FEATURED BLOG - Miguel Ángel Esteve - 08/09/2026 ## LNPs or PNPs that's the question **Discover the key differences between LNPs and PNPs and why payload type is only one factor in platform selection** This article explores how lipid and polymeric nanoparticles differ in composition, delivery performance, regulatory pathways, and manufacturability. You'll learn the main trade-offs between established LNP technologies and the broader design flexibility of PNPs, helping you identify the most suitable platform for a specific therapeutic strategy.   [READ ARTICLE](https://blog.curapath.com/lnps-or-pnps-that-is-the-question) ![pnp vs LNP](https://blog.curapath.com/hs-fs/hubfs/pnp%20vs%20LNP.png?width=1920&height=1080&name=pnp%20vs%20LNP.png) Keep exploring Curapath Blog , there is more NanoTalks yet to explore ## Recent Articles - Filter by: - [All](https://blog.curapath.com/all) - [Polymers](https://blog.curapath.com/tag/polymers) - [LNP](https://blog.curapath.com/tag/lnp) - [Regulatory](https://blog.curapath.com/tag/regulatory) - [Analytics](https://blog.curapath.com/tag/analytics) - [PNP](https://blog.curapath.com/tag/pnp) [![](https://blog.curapath.com/hubfs/pnp%20vs%20LNP.png)](https://blog.curapath.com/lnps-or-pnps-that-is-the-question) [Polymers](https://blog.curapath.com/tag/polymers), [LNP](https://blog.curapath.com/tag/lnp), [PNP](https://blog.curapath.com/tag/pnp) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - September 8, 2026 ### [LNPs or PNPs that is the question](https://blog.curapath.com/lnps-or-pnps-that-is-the-question) Lipid nanoparticles (LNPs) and polymeric nanoparticles (PNPs) are two leading non-viral drug delivery platforms. While... [Read more](https://blog.curapath.com/lnps-or-pnps-that-is-the-question) [![](https://blog.curapath.com/hubfs/fotos%20blog%20july.png)](https://blog.curapath.com/selecting-the-right-polymer-excipient-for-drug-delivery) [Polymers](https://blog.curapath.com/tag/polymers), [Regulatory](https://blog.curapath.com/tag/regulatory) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - July 30, 2026 ### [Selecting the Right Polymer Excipient for Drug Delivery](https://blog.curapath.com/selecting-the-right-polymer-excipient-for-drug-delivery) Historically polymer excipients have been described as inactive formulation components. In today's drug delivery... [Read more](https://blog.curapath.com/selecting-the-right-polymer-excipient-for-drug-delivery) [![](https://blog.curapath.com/hubfs/fotos%20blog%20(10).png)](https://blog.curapath.com/when-does-a-polymer-need-to-be-gmp-grade) [Polymers](https://blog.curapath.com/tag/polymers), [Regulatory](https://blog.curapath.com/tag/regulatory) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - June 25, 2026 ### [When Does a Polymer Need to Be GMP Grade?](https://blog.curapath.com/when-does-a-polymer-need-to-be-gmp-grade) Polymers play a wide variety of rolesin today´s pharmaceutical landscape. They are used as excipients, drug delivery... [Read more](https://blog.curapath.com/when-does-a-polymer-need-to-be-gmp-grade) [![](https://blog.curapath.com/hubfs/fotos%20blog%20(4)-1.jpg)](https://blog.curapath.com/polymers-for-drug-conjugation) [Polymers](https://blog.curapath.com/tag/polymers) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - May 26, 2026 ### [Polymers for Drug Conjugation: From PEGylation to Next-Generation Polymer Therapeutics](https://blog.curapath.com/polymers-for-drug-conjugation) In polymer–drug conjugates, the polymer is not only a passive carrier. Its chemistry, molecular weight, architecture,... [Read more](https://blog.curapath.com/polymers-for-drug-conjugation) [![Targeted LNPs](https://blog.curapath.com/hubfs/fotos%20blog%20(5).png)](https://blog.curapath.com/active-targeting-in-lnps-why-surface-functionalization-matters) [LNP](https://blog.curapath.com/tag/lnp) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - April 28, 2026 ### [Active Targeting in LNPs: Why Surface Functionalization Matters](https://blog.curapath.com/active-targeting-in-lnps-why-surface-functionalization-matters) Active targeting has emerged as one of the most promising strategies to unlock extrahepatic delivery of nanoparticles,... [Read more](https://blog.curapath.com/active-targeting-in-lnps-why-surface-functionalization-matters) [![LNP manufacturing](https://blog.curapath.com/hubfs/fotos%20blog%20(3).png)](https://blog.curapath.com/lnp-manufacturing-process) [LNP](https://blog.curapath.com/tag/lnp) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - April 2, 2026 ### [LNP Manufacturing Process: From Formulation to GMP Production](https://blog.curapath.com/lnp-manufacturing-process) The outcome of this step directly defines critical quality attributes, including: Particle size Polydispersity index... [Read more](https://blog.curapath.com/lnp-manufacturing-process) [![](https://blog.curapath.com/hubfs/fotos%20blog%20(2).png)](https://blog.curapath.com/advanced-analytical-characterization-of-polymeric-excipients) [Polymers](https://blog.curapath.com/tag/polymers), [LNP](https://blog.curapath.com/tag/lnp), [Analytics](https://blog.curapath.com/tag/analytics) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - February 26, 2026 ### [Advanced Analytical Characterization of Polymeric Excipients](https://blog.curapath.com/advanced-analytical-characterization-of-polymeric-excipients) Polymeric excipients play a critical role in modern therapeutic systems being a fundamental partin advanced and highly... [Read more](https://blog.curapath.com/advanced-analytical-characterization-of-polymeric-excipients) [![](https://blog.curapath.com/hubfs/fotos%20blog%20(1).png)](https://blog.curapath.com/antibacterial-polymers-for-medical-devices) [Polymers](https://blog.curapath.com/tag/polymers) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - January 29, 2026 ### [Antibacterial polymers for medical devices](https://blog.curapath.com/antibacterial-polymers-for-medical-devices) Medical device–associated infections remain a major challenge across healthcare, especially for catheters, orthopedic... [Read more](https://blog.curapath.com/antibacterial-polymers-for-medical-devices) [![](https://blog.curapath.com/hubfs/fotos%20blog%20(1).jpg)](https://blog.curapath.com/polymer-drug-conjugates-explained) [Polymers](https://blog.curapath.com/tag/polymers) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - December 18, 2025 ### [Polymer-Drug Conjugates Explained](https://blog.curapath.com/polymer-drug-conjugates-explained) Polymer–drug conjugates (PDCs) represents a unique strategy in modern drug delivery: instead of encapsulating a drug... [Read more](https://blog.curapath.com/polymer-drug-conjugates-explained) [![](https://blog.curapath.com/hubfs/fotos%20blog.jpg)](https://blog.curapath.com/beyond-lipids-and-polymers-understanding-hybrid-nanoparticles) [Polymers](https://blog.curapath.com/tag/polymers), [LNP](https://blog.curapath.com/tag/lnp) - [Miguel Ángel Esteve](https://blog.curapath.com/author/miguel-ángel-esteve) - November 13, 2025 ### [Beyond Lipids and Polymers: Understanding Hybrid Nanoparticles](https://blog.curapath.com/beyond-lipids-and-polymers-understanding-hybrid-nanoparticles) Lipid–polymer hybrid nanoparticles (LPHNs) are emerging as one of the most promising platforms in nanomedicine.... [Read more](https://blog.curapath.com/beyond-lipids-and-polymers-understanding-hybrid-nanoparticles) PREVIOUS [1](https://blog.curapath.com) [2](https://blog.curapath.com/page/2) [3](https://blog.curapath.com/page/3) [NEXT](https://blog.curapath.com/page/2) Keep updated ### Sign Up for NanoTalks Subscribe to NanoTalks, the magazine of Curapath. Stay up to date on the latest developments, trends and news in the world of non-viral vectors, plus discover the latest advances in nanobiotechnology.  [![Inverted](https://blog.curapath.com/hs-fs/hubfs/Inverted.png?width=300&height=113&name=Inverted.png "Inverted")](https://curapath.com/) Toggle 1. [About](https://curapath.com/about-us/) 2. [End-To-End Services](https://curapath.com/end-to-end-services/) 3. [Expertise](https://curapath.com/expertise/) 4. [News & Resources](https://curapath.com/news-events/) 5. [Contact Us](https://curapath.com/contact-us/) --- [Follow us on LinkedIn](https://www.linkedin.com/company/polypeptide-therapeutic-solutions/mycompany/) [Follow us on Twitter](https://curapath.wpengine.com/)